Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 20/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.64 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.64 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.64 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864734 | 0.93 | SLC16A1 (0.62) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5864705 | 0.88 | SLC16A1 (0.69) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5864686 | 0.86 | SLC16A1 (0.67) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5864639 | 0.85 | SLC16A1 (0.65) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5864823 | 0.83 | SLC16A1 (0.70) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5864616 | 0.83 | SLC16A1 (0.63) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5864911 | 0.82 | SLC16A1 (0.61) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5864680 | 0.81 | SLC16A1 (0.66) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5864820 | 0.80 | SLC16A1 (0.80) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 | |
| SCHEMBL5864668 | 0.79 | SLC16A1 (0.79) | SLC16A1CYP2C9MAPKAPK2CAMK2BHIPK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984644-B2 | Treatment of skin disorders using thieno[2,3-D]pyrimidinediones | ASTRAZENECA AB (SE) | 2006-01-10 | — | — | US | claimed |
| US-6469014-B1 | IMMUNOSUPPRESSIVE ACTIVITY | ASTRAZENECA AB (SE) | 2002-10-22 | — | — | US | claimed |
| EP-0991653-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-16 | — | — | EP | claimed |
| US-6984644-B2 | Treatment of skin disorders using thieno[2,3-D]pyrimidinediones | ASTRAZENECA AB (SE) | 2006-01-10 | — | — | US | disclosed |
| US-6469014-B1 | IMMUNOSUPPRESSIVE ACTIVITY | ASTRAZENECA AB (SE) | 2002-10-22 | — | — | US | disclosed |
| EP-0991653-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-16 | — | — | EP | disclosed |